PMID- 21706263
OWN - NLM
STAT- MEDLINE
DCOM- 20120605
LR  - 20161020
IS  - 1439-7609 (Electronic)
IS  - 1439-7595 (Linking)
VI  - 22
IP  - 1
DP  - 2012 Feb
TI  - Etanercept in combination with conventional disease-modifying antirheumatic drugs 
      (DMARDs) in the treatment of rheumatoid arthritis patients intolerant to 
      methotrexate.
PG  - 100-8
LID - 10.1007/s10165-011-0478-8 [doi]
AB  - Although etanercept (ETN) is effective when used in monotherapy for the treatment 
      of rheumatoid arthritis (RA), ETN/methotrexate (MTX) combination therapy is more 
      efficacious. However, some patients show MTX intolerance; these patients may 
      develop adverse events (AEs) or have risk factors for AEs. There is limited 
      published information regarding the efficacy of combination therapy involving ETN 
      and disease-modifying antirheumatic drugs other than MTX. Therefore, we evaluated 
      the effects of combination therapy with ETN and salazosulfapyridine (SASP) and/or 
      bucillamine (Bc), a D: -penicillamine analogue, in MTX-intolerant RA patients. 
      Indices of RA activity, including disease activity score in 28 joints (DAS28), 
      were retrospectively analyzed over a 48-week period in 66 patients treated with 
      ETN. Treatment efficacy was compared in the following 4 major treatment groups: 
      ETN monotherapy, ETN + MTX, ETN + SASP, and ETN + SASP + Bc. Although intergroup 
      differences in the percent change of DAS were not statistically significant, ETN 
      + SASP + Bc seemed to be more effective than ETN monotherapy, and the efficacy of 
      ETN + SASP + Bc was comparable to that of ETN + MTX according to the European 
      League Against Rheumatism (EULAR) improvement ratings. These results suggest that 
      ETN + SASP + Bc combination therapy may be a viable option for RA treatment in 
      patients in whom MTX cannot be used.
FAU - Koyama, Yoshinobu
AU  - Koyama Y
AD  - Center for Rheumatic Diseases, Iizuka Hospital, 3-83 Yoshiomachi, Iizuka, Fukuoka 
      820-8505, Japan. ykoyama@gaea.ocn.ne.jp
FAU - Shiraishi, Hirokazu
AU  - Shiraishi H
FAU - Ohta, Toshiyuki
AU  - Ohta T
FAU - Uchino, Ayumi
AU  - Uchino A
LA  - eng
PT  - Journal Article
DEP - 20110625
PL  - England
TA  - Mod Rheumatol
JT  - Modern rheumatology
JID - 100959226
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 3XC8GUZ6CB (Sulfasalazine)
RN  - K848JZ4886 (Cysteine)
RN  - OP401G7OJC (Etanercept)
RN  - R80LRA5WTF (bucillamine)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/diagnosis/*drug therapy/physiopathology
MH  - Cysteine/analogs & derivatives/therapeutic use
MH  - Drug Substitution
MH  - Drug Therapy, Combination
MH  - Etanercept
MH  - Female
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Immunoglobulin G/*therapeutic use
MH  - Joints/drug effects/physiopathology
MH  - Male
MH  - Methotrexate/*adverse effects
MH  - Middle Aged
MH  - Pain Measurement
MH  - Receptors, Tumor Necrosis Factor/*therapeutic use
MH  - Recovery of Function
MH  - Retrospective Studies
MH  - Severity of Illness Index
MH  - Sulfasalazine/therapeutic use
MH  - Treatment Failure
EDAT- 2011/06/28 06:00
MHDA- 2012/06/06 06:00
CRDT- 2011/06/28 06:00
PHST- 2011/02/23 00:00 [received]
PHST- 2011/05/23 00:00 [accepted]
PHST- 2011/06/28 06:00 [entrez]
PHST- 2011/06/28 06:00 [pubmed]
PHST- 2012/06/06 06:00 [medline]
AID - 10.1007/s10165-011-0478-8 [doi]
PST - ppublish
SO  - Mod Rheumatol. 2012 Feb;22(1):100-8. doi: 10.1007/s10165-011-0478-8. Epub 2011 
      Jun 25.